Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
NCT00030498 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75
Last updated 2013-01-16
Summary
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
Conditions
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- Adult Brain Stem Glioma
- Adult Diffuse Astrocytoma
- Adult Ependymoblastoma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Mixed Glioma
- Adult Myxopapillary Ependymoma
- Adult Oligodendroglioma
- Adult Pilocytic Astrocytoma
- Adult Primary Hepatocellular Carcinoma
- Adult Subependymoma
- Advanced Adult Primary Liver Cancer
- Advanced Malignant Mesothelioma
- Male Breast Cancer
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Recurrent Adult Brain Tumor
- Recurrent Adult Primary Liver Cancer
- Recurrent Anal Cancer
- Recurrent Basal Cell Carcinoma of the Lip
- Recurrent Bladder Cancer
- Recurrent Breast Cancer
- Recurrent Cervical Cancer
- Recurrent Colon Cancer
- Recurrent Esophageal Cancer
- Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Recurrent Lymphoepithelioma of the Nasopharynx
- Recurrent Lymphoepithelioma of the Oropharynx
- Recurrent Malignant Mesothelioma
- Recurrent Metastatic Squamous Neck Cancer With Occult Primary
- Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
- Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
- Recurrent Non-small Cell Lung Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Pancreatic Cancer
- Recurrent Prostate Cancer
- Recurrent Rectal Cancer
- Recurrent Salivary Gland Cancer
- Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Recurrent Squamous Cell Carcinoma of the Larynx
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Recurrent Squamous Cell Carcinoma of the Nasopharynx
- Recurrent Squamous Cell Carcinoma of the Oropharynx
- Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Recurrent Verrucous Carcinoma of the Larynx
- Recurrent Verrucous Carcinoma of the Oral Cavity
- Stage II Esophageal Cancer
- Stage II Pancreatic Cancer
- Stage III Esophageal Cancer
- Stage III Pancreatic Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Adenoid Cystic Carcinoma of the Oral Cavity
- Stage IV Anal Cancer
- Stage IV Basal Cell Carcinoma of the Lip
- Stage IV Bladder Cancer
- Stage IV Breast Cancer
- Stage IV Colon Cancer
- Stage IV Esophageal Cancer
- Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Stage IV Lymphoepithelioma of the Nasopharynx
- Stage IV Lymphoepithelioma of the Oropharynx
- Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
- Stage IV Mucoepidermoid Carcinoma of the Oral Cavity
- Stage IV Non-small Cell Lung Cancer
- Stage IV Ovarian Epithelial Cancer
- Stage IV Pancreatic Cancer
- Stage IV Prostate Cancer
- Stage IV Rectal Cancer
- Stage IV Salivary Gland Cancer
- Stage IV Squamous Cell Carcinoma of the Hypopharynx
- Stage IV Squamous Cell Carcinoma of the Larynx
- Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IV Squamous Cell Carcinoma of the Nasopharynx
- Stage IV Squamous Cell Carcinoma of the Oropharynx
- Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Stage IV Verrucous Carcinoma of the Larynx
- Stage IV Verrucous Carcinoma of the Oral Cavity
- Stage IVA Cervical Cancer
- Stage IVB Cervical Cancer
- Unspecified Adult Solid Tumor, Protocol Specific
- Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
- DRUG
-
erlotinib hydrochloride
Given orally
- OTHER
-
laboratory biomarker analysis
Correlative studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Antonius Miller · Cancer and Leukemia Group B
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-12-31
- Primary Completion
- 2007-07-31
Countries
- United States
Study Locations
More Related Trials
-
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
NCT01193881 ·Status: TERMINATED ·Phase: PHASE1
-
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
NCT02535338 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00550537 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
NCT00997334 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
NCT00988169 ·Status: TERMINATED ·Phase: PHASE2
-
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00778167 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
NCT00139620 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
NCT02699606 ·Status: COMPLETED ·Phase: PHASE2
-
Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer
NCT00579683 ·Status: COMPLETED
-
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
NCT00983307 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung
NCT01013831 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
NCT01998126 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
NCT01230710 ·Status: COMPLETED ·Phase: PHASE4
-
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
NCT00567359 ·Status: COMPLETED ·Phase: PHASE2
-
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
NCT05017025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of ARQ 197 in Combination With Erlotinib
NCT01069757 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21
NCT01714908 ·Status: UNKNOWN ·Phase: PHASE2
-
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
NCT05493501 ·Status: TERMINATED ·Phase: PHASE3
-
Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection
NCT00087269 ·Status: TERMINATED ·Phase: PHASE2
-
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
NCT02134886 ·Status: TERMINATED ·Phase: PHASE1
-
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
NCT00673049 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
NCT01101334 ·Status: COMPLETED ·Phase: PHASE2
-
A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer
NCT02595450 ·Status: COMPLETED
-
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
NCT01609543 ·Status: COMPLETED ·Phase: PHASE4
-
Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00072072 ·Status: COMPLETED ·Phase: PHASE1